843 filings
Page 13 of 43
CORRESP
8ilhwiusdc7 y2k
21 May 21
Correspondence with SEC
12:00am
8-K
tmgm5 1jb
20 May 21
Departure of Directors or Certain Officers
5:18pm
UPLOAD
yoafh6ic0bum9uonm3
19 May 21
Letter from SEC
12:00am
8-K
icyzl4z9c56 gcyjrozt
17 May 21
CytoDyn Signs Distribution Agreement with Macleods Pharmaceuticals Ltd. to Pursue EUA and Compassionate Use Access to Leronlimab in India
5:00pm
CORRESP
5fa6xut7hdcnuqk54b
7 May 21
Correspondence with SEC
12:00am
8-K
8l2sj1ca0o6 dd9
29 Apr 21
Entry into a Material Definitive Agreement
4:30pm
8-K
841 6wsnvm0g0q
21 Apr 21
Entry into a Material Definitive Agreement
4:31pm
UPLOAD
bbxvo pgw1uzeh1
16 Apr 21
Letter from SEC
12:00am
8-K
okwmdo6c52qpei
12 Apr 21
CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications
4:30pm
8-K
r34px7xn
8 Apr 21
Entry into a Material Definitive Agreement
8:33am
8-K
2qk2l
7 Apr 21
Regulation FD Disclosure
4:01pm
CORRESP
bn7azd gz2y
23 Mar 21
Correspondence with SEC
12:00am
8-K
oni3m6fl7emry
16 Mar 21
CytoDyn Appoints Christopher Recknor, M.D., as Chief Operating Officer
8:30am
8-K
fcvp249q g1e9t
8 Mar 21
Regulation FD Disclosure
5:27pm
8-K
hubde3 tgim8mcvdiwrp
2 Mar 21
In the Court of Chancery of the State of Delaware
8:31am
UPLOAD
og5n m5nej2nnceq05
18 Feb 21
Letter from SEC
12:00am
8-K
ljdjqxga
29 Jan 21
Entry into a Material Definitive Agreement
8:31am
EFFECT
bfkmjupwr5b7zcw7
25 Jan 21
Notice of effectiveness
12:19am